DeCure for Burkitts lymphoma

The 1976 trial of combined chemotherapy, radiotherapy, and immunotherapy in fifteen American patients with Burkitt's lymphoma reported that two patients died during induction, while thirteen achieved complete responses. Eight patients relapsed at a median of 11 weeks from initial treatment, and seven of these died; one patient achieved a prolonged third remission after intensive chemotherapy and bone marrow autograft. Five patients remained in first remission beyond one year. The authors identified prevention of relapse as the major therapeutic goal.

A 2006 Cochrane review of therapeutic interventions for Burkitt's lymphoma in children identified twelve randomised controlled trials meeting entry criteria, but data could only be retrieved from ten. Inadequate reporting of study methodology was common, preventing thorough quality assessment, and data could not be pooled due to differences between interventions. Overall survival did not differ significantly between treatment groups in three of four studies reporting this outcome for remission induction. In two of three studies reporting survival for remission maintenance, survival was substantially but not statistically significantly different between groups. The review concluded there was no strong evidence on the relative effectiveness of interventions, with studies described as small, underpowered, and prone to systematic and random error.

A 2003 review of molecular pathogenesis noted that the WHO classification recognises three subcategories of Burkitt's lymphoma—endemic, non-endemic, and immunodeficiency-associated—and that immunohistochemistry and molecular studies point to heterogeneity, suggesting AIDS-related Burkitt's lymphoma may have a different pathogenesis from classic disease. A 2010 review stated that therapeutic strategies remain a challenge because of significant toxicities and poor prognosis, calling for further studies into molecular mechanisms of carcinogenesis, chemotherapy, and drug resistance. A 2011 commentary noted that while childhood acute lymphoblastic leukaemia cure rates exceed 80%, the minority of patients who fail to achieve long-term remission have limited options and poor prognosis, and stated much the same could be said for Burkitt's lymphoma.

A 2018 chapter described Burkitt's lymphoma as highly aggressive with one of the highest proliferation rates in malignancies, with frequent extranodal involvement and possible generalisation to acute leukaemia challenging effective treatment, which normally consists of poly-agent chemotherapy. A 2023 case report of Burkitt's lymphoma in the palatine tonsil of a young adult emphasised the tumour's rarity in adults, high aggressiveness, and the importance of timely diagnosis to improve prognosis. Across these sources, no drug is identified as a repurposing candidate, and no trial data support any specific targeted agent. What remains missing is any randomised evidence comparing modern regimens, reliable biomarkers for patient stratification, and adequately powered trials that can detect survival differences rather than the small, underpowered studies that have characterised the field to date.